8-K: Barinthus Bio Updates Merger, Delisting Plans

Barinthus Bio announces key dates and ratio determination for its combination with Clywedog Therapeutics, confirming delisting from Nasdaq.

Summary

• Barinthus Biotherapeutics plc has provided an update on its proposed combination with Clywedog Therapeutics, Inc.
• The company has determined the Scheme Exchange Ratio to be 0.111, ensuring Topco's common stock meets Nasdaq listing requirements.
• Barinthus Bio has notified Nasdaq of its intent to withdraw its American Depositary Shares (ADSs) from listing.
• Trading of the ADSs on Nasdaq is expected to halt before the market opens on September 3, 2026.
• Following the merger's completion, Topco will be renamed Clywedog Therapeutics Holdings, Inc., and its common stock will trade on Nasdaq under the symbol CLYD.
• The company's application for the merger transactions will be heard by the High Court in London on September 1, 2026.
• Barinthus Bio is a clinical-stage biopharmaceutical company focused on immunotherapeutics for autoimmunity and chronic infectious diseases.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, primarily focused on regulatory and procedural steps for a previously announced merger, with no new financial performance data.

Positives

• The Scheme Exchange Ratio has been determined at 0.111, which is sufficient to meet Nasdaq's minimum price requirement for the combined company's stock.
• The proposed combination with Clywedog Therapeutics is progressing with key procedural steps being met.
• The combined company's common stock is planned to be listed on Nasdaq under the ticker symbol CLYD, providing continued market access.

Negatives

• Barinthus Bio's American Depositary Shares (ADSs) will be delisted from Nasdaq.
• Trading of the ADSs will halt prior to the opening of trading on September 3, 2026, indicating a transition away from the current listing.
• The company will cease to be a publicly reporting entity under Sections 13 and 15(d) of the Exchange Act following the effectiveness of Form 15.

Risks

• The risk that the proposed transaction may not be completed in a timely manner or at all.
• The risk that the proposed transaction may involve unexpected costs, liabilities or delays.
• The risk that the anticipated benefits of the proposed transaction may not be fully realized or may take longer to realize than expected.
• Risks related to the value of the combined company securities to be issued in the proposed transaction.
• Risks associated with global economic uncertainty, including disruptions in the banking industry, conflicts, and disruptions in U.S. federal government operations.
• Risks related to the success, cost, and timing of the company's pipeline development activities and clinical trials.

Future Outlook

The company anticipates the scheme of arrangement to become effective on September 3, 2026, with trading of its ADSs on Nasdaq halting prior to that date. Following the merger, the combined entity's common stock is expected to trade on Nasdaq under the symbol CLYD.

Management Comments

• Barinthus Bio provides an update on the anticipated closing of its proposed combination with Clywedog Therapeutics, Inc. in an all-stock transaction.
• The Board of Directors determined the Scheme Exchange Ratio is 0.111, ensuring Topco's common stock meets Nasdaq listing requirements.
• Trading of the ADSs on Nasdaq is expected to halt prior to the opening of trading on September 3, 2026.

Industry Context

StockSavvy.ai notes that this filing reflects a common trend in the biopharmaceutical industry where clinical-stage companies pursue combinations to leverage complementary platforms or achieve economies of scale, often involving a change in listing or ticker symbol.

Legal Proceedings

• The company's application regarding the merger transactions is scheduled to be heard before a High Court Judge on September 1, 2026.

Stakeholder Impact

• Shareholders will exchange their Barinthus Bio ADSs for shares in the combined company, Clywedog Therapeutics Holdings, Inc., which will be listed under a new ticker symbol (CLYD).
• The delisting of Barinthus Bio ADSs from Nasdaq will change the trading venue for existing shareholders.
• The company's reporting obligations under Sections 13 and 15(d) of the Exchange Act will be suspended, potentially reducing public disclosure requirements for the combined entity.

Next Steps

• The scheme of arrangement is expected to become effective on September 3, 2026.
• Trading of Barinthus Bio ADSs on Nasdaq is expected to halt prior to the opening of trading on September 3, 2026.
• Following the completion of the merger, Topco will be renamed Clywedog Therapeutics Holdings, Inc.
• The common stock of the combined company is expected to be listed on Nasdaq under the ticker symbol CLYD.
• The company intends to file a Form 15 to deregister its ADSs and suspend its reporting obligations under Sections 13 and 15(d) of the Exchange Act.

Key Dates

Keywords

Merger, Combination, Delisting, Biotherapeutics, Clinical Stage, Immunotherapeutics, Autoimmunity, Nasdaq